Abivax doses first patient in phase 2b/3 COVID-19 clinical trial pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy
March 5, 2021 GMT
The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients
Lower than expected rate (10.1%) of progression to severe disease or death with no difference between ABX464 and placebo groups
Decision has no impact on ABX464 development in chronic inflammatory indications
ABX464 top-line clinical data expected in Q2 2021 for phase 2b ulcerative colitis trial and phase 2a rheumatoid arthritis trial
ABIVAX
Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
DGAP-News: ABIVAX / Key word(s): Study
Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
05.03.2021 / 20:00
Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial
due to lack of efficacy
The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients
Lower than expected rate (10.1%) of progression to severe disease or death with no difference between ABX464 and placebo groups
Decision has no impact on ABX464 development in chronic inflammatory indications
Covid-19 : le couvre-feu avancé à 18 heures est-il efficace ? francetvinfo.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from francetvinfo.fr Daily Mail and Mail on Sunday newspapers.